This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Echo Therapeutics, Inc. (Nasdaq: ECTE) Provides An Update To Shareholders

PHILADELPHIA, Jan. 7, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony ® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today issued the following corporate update to its shareholders:

To Our Shareholders:

As we begin the new year, we are pleased to report that the last year was one of significant accomplishment and progress that has set the stage for a very exciting and productive 2013.  In this letter, we would like to reflect on our achievements and, more importantly, look forward to the objectives we intend to achieve in the coming months.

2012 Business Review

Over the past year we achieved several major milestones:

  • In 2012, Echo completed two clinical trials of the Symphony tCGM System in critically ill patients that showed that Symphony successfully monitored patient glucose levels and has the potential to be an important tool for the tracking and trending of glucose in the hospital setting.  To date, Echo has completed ten pilot studies of the Symphony tCGM System with a combined average error rate (MARD) of 12.0%.
  • Echo added key executives to its management team as part of our plan to finalize development and accelerate the commercialization of the Symphony tCGM System and other products contemplated in our growth strategy.
  • Echo's Operations management worked closely with the global electronics manufacturing and distribution provider, Benchmark Electronics, Inc., to provide the necessary tools and processes for the product launch of the Symphony tCGM System.
  • At the 72 nd Annual Scientific Sessions of the American Diabetes Association on June 8, 2012, Echo presented an expanded analysis of data collected from patients with either type 1 or type 2 diabetes during its clinical trial of Symphony.   Echo also presented at the 12 th Annual Diabetes Technology Meeting on November 9, 2012.
  • Echo announced that it obtained several patents throughout the year that provide our products with long-term market protection.  Echo holds eight U.S. patents and 71 foreign patents, and has over 25 pending patent applications in the U.S. and foreign countries.
  • Three additional analysts initiated research on Echo in 20l2, contributing to improved market awareness.   Currently, six investment banks follow Echo:  Ascendiant Capital Markets, Feltl and Company, LifeTech Capital, Noble Financial Capital Markets, Northland Capital Markets, and Wunderlich Securities, Inc.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs